Microbot Medical (MBOT) Financials

Microbot Medical’s latest quarter shows a company with a strong cash position, but also one that is still burning cash and remains pre-revenue. For Q1 2026, MBOT reported just $105,000 in revenue and $3.7 million in net loss, while operating cash outflow was $5.1 million. The positive takeaway is that the balance sheet is currently well-funded, with $72.7 million in cash, restricted cash and short-term investments.

What stands out most is the funding runway. Total current assets were $76.5 million versus only $3.4 million in current liabilities, and total liabilities were just $4.0 million. That leaves MBOT with a very large liquidity cushion relative to its near-term obligations.

• Large liquidity reserve: Cash, restricted cash and short-term investments totaled about $72.7 million in Q1 2026, giving the company substantial flexibility.
• Very strong current ratio: Current assets of $76.5 million versus current liabilities of $3.4 million point to a healthy short-term balance sheet.
• Low leverage: Total liabilities were only $4.0 million, which is modest compared with total assets of $78.1 million.
• Investment income helps offset losses: Q1 2026 interest and investment income of $649,000 meaningfully reduced the pretax loss.
• Operating cash burn improved versus Q4 2025: Operating cash outflow was $5.1 million in Q1 2026 versus $3.8 million in Q4 2025, which is worse in absolute terms, but still manageable given the cash balance.
• Revenue is still minimal: Q1 2026 revenue was only $105,000, so the business has not yet reached meaningful commercial scale.
• Heavy reliance on non-operating income: The company is still not generating enough operating profit to cover expenses, so investment income and capital markets activity remain important.
• Inventory and prepaid assets are present: MBOT held $2.3 million in inventory and $660,000 in prepaid expenses, suggesting some operational build-out, but not enough yet to indicate strong product traction.
• Persistent quarterly losses: Net loss was $3.7 million in Q1 2026, continuing a long pattern of losses.
• Ongoing operating cash burn: Operating activities used $5.1 million in cash in Q1 2026, showing the business is still consuming cash to run.
• Expenses remain far above revenue: Operating expenses of $4.3 million dwarfed revenue of $105,000, underscoring the early-stage nature of the business.
• Share dilution has been significant over time: Weighted average basic shares were 67.2 million in Q1 2026, up sharply from 14.1 million in Q1 2024, indicating substantial dilution for existing shareholders.

Looking at the broader trend over the last four years, MBOT has consistently posted quarterly net losses in the $2.4 million to $3.7 million range and has relied on equity issuance and investment portfolio activity to fund operations. The good news is that the company has built a much stronger cash position than it had in early 2024. The concern is that without a sharp increase in revenue or a reduction in cash burn, that balance could gradually erode.

Bottom line: Microbot Medical is financially stable for now because of its large cash and investment balance, but the operating model is still in the high-risk, pre-profit stage. Investors should watch for revenue traction, lower quarterly cash burn, and evidence that the company can move closer to commercialization without excessive dilution.